Antibe Therapeutics Inc(Pre-Merger) T.ATE

Primary Symbol: ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > The market is bored

<< Previous

Bullboard Posts

Next >>

Comment by woundedkneeon Sep 17, 2020 8:17am

163 Views

Post# 31573122

RE:RE:RE:RE:RE:The market is bored

Based on these timelines i would say that the market will continue to be "bored". Can anyone think of any, (and I restate the word "any") events in the short or medium term that would push the sp up to the 50 to 60 cent mark that was mentioned in a previous post? Of course, not withstanding a consolidation. Does this company, right now, have enough going for it to be bought out before phase111 trials, or even before a RS. And does Antibe move to the Nasdaq before phase111? I believe Dan suggested as much. Although I could be wrong.

<< Previous

Bullboard Posts

Next >>

A junior copper-gold stock trading at a bargain of monumental proportions